Mark Robinson has over 30 years of investment banking experience, advising many of the most prominent pharmaceutical, biotechnology, and medical device companies in the healthcare industry.
Mr. Robinson joined Centerview in 2009 to establish its healthcare practice after 12 years at Merrill Lynch, having served as the Global Co-Head of Healthcare Investment Banking for the last six years.
Selected advisory assignments while at Centerview include:
- Seagen on its $44.5 billion acquisition by Pfizer
- Immunomedics on its $21.0 billion acquisition by Gilead
- Pharmacyclics on its $21.0 billion sale to Abbvie
- MyoKardia on its $13.1 billion acquisition by Bristol Myers Squibb
- Array Biopharma on its $11.8 billion sale to Pfizer
- Onyx on its $10.4 billion sale to Amgen
- InterMune on its $8.9 billion sale to Roche
- AveXis on its $8.7 billion sale to Novartis
- Cerevel on its $8.7 billion sale to AbbVie
- Receptos on its $7.8 billion sale to Celgene
- GW Pharma on its $7.2 billion sale to Jazz
- Momenta on its $6.5 billion acquisition by Johnson & Johnson
- Global Blood Therapeutics on its $5.8 billion sale to Pfizer
- Mirati Therapeutics on its up to $5.8 billion sale to Bristol Myers Squibb
- Auris Health on its sale for up to $5.8 billion to Johnson & Johnson
- Tesaro on its $5.1 billion sale to GlaxoSmithKline
- Alpine Immune Sciences on its $4.95 billion sale to Vertex
- Forty-Seven on its $4.9 billion sale to Gilead
- Spark on its $4.8 billion sale to Roche
- CymaBay on its $4.3 billion sale to Gilead
- OSI on its hostile defense and $4.0 billion sale to Astellas
- Idenix on its $3.8 billion sale to Merck
- Avanir on its $3.5 billion sale to Otsuka
- Dicerna on its $3.3 billion sale to Novo Nordisk
- Translate Bio on its $3.2 billion sale to Sanofi
- Audentes on its $3.0 billion sale to Astellas
- Alder BioPharmaceuticals on its $2.0 billion sale to Lundbeck
- Tobira on its sale for up to $1.7 billion to Allergan
- Portola on its $1.6 billion sale to Alexion
- Relypsa on its $1.5 billion sale to Galenica
Notable transactions at Merrill Lynch include advising Immunex in its $16 billion sale to Amgen, IDEC in its $7 billion merger with Biogen to create Biogen Idec, Boston Scientific in its $25 billion hostile acquisition of Guidant, Vertex in its acquisition of Aurora and Illumina in its purchase of Solexa. From the beginning of his career in 1993, until he left Merrill Lynch, Mr. Robinson was a leading advisor in raising capital for companies in the biotechnology and medical device industries.
He earned a B.A. from the University of California Berkeley and an M.B.A. from Harvard Business School.
Mr. Robinson is a Regent of the University of California. He previously served as the Chairman of the Board of the College of Letters and Science at U.C. Berkeley as well as a member of the Board of Trustees of the U.C. Berkeley Foundation. He is a Trustee of The Thacher School as well as a member of the Council on Foreign Relations.